BrainXell
PrivateLast Round
Grant
Aug 8, 2023
Total Funding Raised
$19.66M
Company Overview
BrainXell operates in Healthcare & Life Sciences and is based in Madison, Wisconsin. Its latest recorded funding round was a Grant round in August 2023.
BrainXell is a biotechnology company that manufactures customized nervous system cells derived from human stem cell lines for use in research and drug discovery.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine
Business Model
B2B
Customer Profile
Hardware Sales, Services & Consulting, Government Contracts
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
BrainXell Comparables
Compare BrainXell with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| iXCells Biotechnologies | 88% | |
| NeuCyte | 87% | |
| Axol Bioscience | 86% |
For institutional investors. Book with your work email.
BrainXell Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Aug 8, 2023 | ||||
| Series B | Sep 28, 2021 | ||||
| Accelerator | Nov 1, 2016 | ||||
| Grant | Sep 1, 2016 |
For institutional investors. Book with your work email.
BrainXell Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| NIH RADx | Grant |
| Wisconsin Economic Development Corporation | Grant |
| WARF Ventures | Series B |
| Discovery to Product | Accelerator |
| California Institute for Regenerative Medicine | Grant |
| National Institute of Neurological Disorders and Stroke | Grant |
| National Institute of Mental Health | Grant |
Market signals
Structured signals derived from secondary market and firmographic data.
- Nov 15, 2025
Presented Parkinson's therapy candidate at the Society for Neuroscience Annual Meeting.
- Nov 15, 2025
Showcased iPSC research and in vivo data for Parkinson's therapy candidate BXT-110.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- is_developingNov 12, 2026
BrainXell, Inc. uses its stem cell differentiation expertise to develop specialised neural cell models incorporating Promega's NanoLuc, NanoBiT and HaloTag technologies for research into protein behaviour in human neural models.
For institutional investors. Book with your work email.
BrainXell Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about BrainXell's valuation, stock price, and market status.
Is BrainXell a public or private company?
BrainXell is a private company.
What is the current stock price of BrainXell?
BrainXell is a private company, so its shares have no public market price. Caplight tracks BrainXell's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is BrainXell worth (valuation)?
Valuation information for BrainXell is not publicly available.
Can I buy BrainXell stock?
BrainXell shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was BrainXell's last funding round?
BrainXell's most recent funding round was Grant on August 8, 2023.
Who are the main investors in BrainXell?
Key investors in BrainXell include NIH RADx, Wisconsin Economic Development Corporation, WARF Ventures, Discovery to Product, California Institute for Regenerative Medicine.
Will BrainXell IPO soon?
No public IPO plans have been announced for BrainXell.
How can I track BrainXell secondary market activity?
Caplight tracks bids, offers, and trades in BrainXell's shares on secondary markets.